Temocillin

Tiffeny T. Smith, Sara Cosgrove

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Temocillin (BRL 17421) is a beta-lactam antibiotic, which is the 6-alpha-methoxy derivative of ticarcillin (see Chapter 9, Carbenicillin, carindacillin, carfecillin and ticarcillin). It has activity against aerobic Gram-negative bacteria except for Pseudomonas aeruginosa and Acinetobacter spp. Temocillin is stable against most types of beta-lactamases, including extended-spectrum and AmpC beta-lactamases (Solocombe et al., 1981). Temocillin is available in Belgium (Negaban), Luxembourg, and the UK as a parenteral antibiotic for the treatment of Gram-negative infections. Both the European Medicines Agency (EMEA) and the US Food and Drug Administration (FDA) have given temocillin orphan drug status for the treatment of infections caused by Burkholderia cepacia in patients with cystic fibrosis.

Original languageEnglish (US)
Title of host publicationKucers the Use of Antibiotics
Subtitle of host publicationA Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition
PublisherCRC Press
Pages218-224
Number of pages7
ISBN (Electronic)9781498747967
ISBN (Print)9781498747950
DOIs
StatePublished - Jan 1 2017

Fingerprint

Ticarcillin
Carfecillin
Gram-Negative Aerobic Bacteria
Luxembourg
Orphan Drug Production
Anti-Bacterial Agents
Carbenicillin
Burkholderia cepacia
Acinetobacter
Belgium
beta-Lactams
United States Food and Drug Administration
beta-Lactamases
Infection
Cystic Fibrosis
Pseudomonas aeruginosa
temocillin
Therapeutics
carbenicillin indanyl
AmpC beta-lactamases

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Smith, T. T., & Cosgrove, S. (2017). Temocillin. In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition (pp. 218-224). CRC Press. https://doi.org/10.1201/9781315152110

Temocillin. / Smith, Tiffeny T.; Cosgrove, Sara.

Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press, 2017. p. 218-224.

Research output: Chapter in Book/Report/Conference proceedingChapter

Smith, TT & Cosgrove, S 2017, Temocillin. in Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press, pp. 218-224. https://doi.org/10.1201/9781315152110
Smith TT, Cosgrove S. Temocillin. In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press. 2017. p. 218-224 https://doi.org/10.1201/9781315152110
Smith, Tiffeny T. ; Cosgrove, Sara. / Temocillin. Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press, 2017. pp. 218-224
@inbook{6b7fdd450a4a44b5979ba8bc350acc01,
title = "Temocillin",
abstract = "Temocillin (BRL 17421) is a beta-lactam antibiotic, which is the 6-alpha-methoxy derivative of ticarcillin (see Chapter 9, Carbenicillin, carindacillin, carfecillin and ticarcillin). It has activity against aerobic Gram-negative bacteria except for Pseudomonas aeruginosa and Acinetobacter spp. Temocillin is stable against most types of beta-lactamases, including extended-spectrum and AmpC beta-lactamases (Solocombe et al., 1981). Temocillin is available in Belgium (Negaban), Luxembourg, and the UK as a parenteral antibiotic for the treatment of Gram-negative infections. Both the European Medicines Agency (EMEA) and the US Food and Drug Administration (FDA) have given temocillin orphan drug status for the treatment of infections caused by Burkholderia cepacia in patients with cystic fibrosis.",
author = "Smith, {Tiffeny T.} and Sara Cosgrove",
year = "2017",
month = "1",
day = "1",
doi = "10.1201/9781315152110",
language = "English (US)",
isbn = "9781498747950",
pages = "218--224",
booktitle = "Kucers the Use of Antibiotics",
publisher = "CRC Press",
address = "United States",

}

TY - CHAP

T1 - Temocillin

AU - Smith, Tiffeny T.

AU - Cosgrove, Sara

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Temocillin (BRL 17421) is a beta-lactam antibiotic, which is the 6-alpha-methoxy derivative of ticarcillin (see Chapter 9, Carbenicillin, carindacillin, carfecillin and ticarcillin). It has activity against aerobic Gram-negative bacteria except for Pseudomonas aeruginosa and Acinetobacter spp. Temocillin is stable against most types of beta-lactamases, including extended-spectrum and AmpC beta-lactamases (Solocombe et al., 1981). Temocillin is available in Belgium (Negaban), Luxembourg, and the UK as a parenteral antibiotic for the treatment of Gram-negative infections. Both the European Medicines Agency (EMEA) and the US Food and Drug Administration (FDA) have given temocillin orphan drug status for the treatment of infections caused by Burkholderia cepacia in patients with cystic fibrosis.

AB - Temocillin (BRL 17421) is a beta-lactam antibiotic, which is the 6-alpha-methoxy derivative of ticarcillin (see Chapter 9, Carbenicillin, carindacillin, carfecillin and ticarcillin). It has activity against aerobic Gram-negative bacteria except for Pseudomonas aeruginosa and Acinetobacter spp. Temocillin is stable against most types of beta-lactamases, including extended-spectrum and AmpC beta-lactamases (Solocombe et al., 1981). Temocillin is available in Belgium (Negaban), Luxembourg, and the UK as a parenteral antibiotic for the treatment of Gram-negative infections. Both the European Medicines Agency (EMEA) and the US Food and Drug Administration (FDA) have given temocillin orphan drug status for the treatment of infections caused by Burkholderia cepacia in patients with cystic fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=85056677351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056677351&partnerID=8YFLogxK

U2 - 10.1201/9781315152110

DO - 10.1201/9781315152110

M3 - Chapter

AN - SCOPUS:85056677351

SN - 9781498747950

SP - 218

EP - 224

BT - Kucers the Use of Antibiotics

PB - CRC Press

ER -